UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $118.21 Million Position in United Therapeutics Corporation $UTHR

Posted by Brian Himes on Sep 2nd, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 5.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 218,164 shares of the biotechnology company’s stock after purchasing an additional 10,855 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.51% of United Therapeutics worth $118,208,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Toth Financial Advisory Corp boosted its stake in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares during the period. Fiduciary Financial Advisors bought a new position in United Therapeutics in the 2nd quarter worth approximately $30,000. WealthCollab LLC increased its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $165,819,572.87. The trade was a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 414,075 shares of company stock worth $221,222,045 in the last three months. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada reduced their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Read Our Latest Report on UTHR

United Therapeutics Trading Up 0.5%

UTHR opened at $512.70 on Wednesday. The stock has a market cap of $21.99 billion, a PE ratio of 18.34, a P/E/G ratio of 2.55 and a beta of 0.56. United Therapeutics Corporation has a 1 year low of $375.61 and a 1 year high of $609.35. The stock’s 50 day simple moving average is $529.27 and its 200-day simple moving average is $539.68.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the business earned $6.41 earnings per share. Equities analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.